Stroke:血管紧张素受体阻断剂和β-阻断剂与老年人卒中发生相关

2016-05-31 phylis 译 MedSci原创

背景:研究旨在确定65岁老年人,不同抗高血压药物及长期血压变异率(BPV)与卒中事件发生的相关性。在老年人≥65年。方法:样本包括5951名受试者(平均年龄74岁,60%名女性),受试者至少服用1种药物治疗高血压(3727/5951)或收缩压>140毫米汞柱或舒张压>90毫米汞柱。在随访的12年中,评估受试者致命性和非致命性卒中事件的发生。对9种类别的降压药,采用变异系数和回归计算BPV(BPVr

背景:研究旨在确定65岁老年人,不同抗高血压药物及长期血压变异率(BPV)与卒中事件发生的相关性。在老年人≥65年。

方法:样本包括5951名受试者(平均年龄74岁,60%名女性),受试者至少服用1种药物治疗高血压(3727/5951)或收缩压>140mmHg或舒张压>90mmHg。在随访的12年中,评估受试者致命性和非致命性卒中事件的发生。对9种类别的降压药,采用变异系数和回归计算BPV(BPVreg)。应用风险模型确定不同药物卒中事件发生的HR,校正血压、BPVreg、协变量和延迟输入偏倚。

结果:随访的中位数为9.1年(四分位间距6.4-10.4),共有273例发生卒中事件。降压药物不能降低卒中风险。血管紧张素受体拮抗剂(HR 1.56;95%CI 1.06-2.28)和β-受体阻滞剂(HR 1.41;95%CI 1.03-1.92)与总卒中风险发生升高相关。校正舒张压BPV,血管紧张素受体拮抗剂和β-受体阻滞剂与缺血性卒中相关。在收缩压分层分析中,收缩压140至160mmHg与卒中发生风险相关(变异系数每增加0.10,HR 1.59;95%CI 1.05-2.40)。

结论:血管紧张素受体阻断剂和β-阻断剂类药物与老年人卒中和缺血性中风发生相关。BPV一般与卒中发生不相关。

原始出处:

Tully PJ, Debette S, et al. Antihypertensive Drug Use, Blood Pressure Variability, and Incident Stroke Risk in Older Adults: Three-City Cohort Study. Stroke. 2016 May.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1816422, encodeId=58b01816422be, content=<a href='/topic/show?id=08049e6803b' target=_blank style='color:#2F92EE;'>#阻断剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97680, encryptionId=08049e6803b, topicName=阻断剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Fri Apr 28 10:39:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710032, encodeId=51ce1e10032d0, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Tue Feb 14 05:39:00 CST 2017, time=2017-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148165, encodeId=74bc148165f6, content=拜读了,受益匪浅,点个赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Oct 14 14:05:44 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589285, encodeId=226d1589285ca, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Thu Jun 02 02:39:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1816422, encodeId=58b01816422be, content=<a href='/topic/show?id=08049e6803b' target=_blank style='color:#2F92EE;'>#阻断剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97680, encryptionId=08049e6803b, topicName=阻断剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Fri Apr 28 10:39:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710032, encodeId=51ce1e10032d0, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Tue Feb 14 05:39:00 CST 2017, time=2017-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148165, encodeId=74bc148165f6, content=拜读了,受益匪浅,点个赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Oct 14 14:05:44 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589285, encodeId=226d1589285ca, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Thu Jun 02 02:39:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1816422, encodeId=58b01816422be, content=<a href='/topic/show?id=08049e6803b' target=_blank style='color:#2F92EE;'>#阻断剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97680, encryptionId=08049e6803b, topicName=阻断剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Fri Apr 28 10:39:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710032, encodeId=51ce1e10032d0, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Tue Feb 14 05:39:00 CST 2017, time=2017-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148165, encodeId=74bc148165f6, content=拜读了,受益匪浅,点个赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Oct 14 14:05:44 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589285, encodeId=226d1589285ca, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Thu Jun 02 02:39:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
    2016-10-14 ylzr123

    拜读了,受益匪浅,点个赞!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1816422, encodeId=58b01816422be, content=<a href='/topic/show?id=08049e6803b' target=_blank style='color:#2F92EE;'>#阻断剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97680, encryptionId=08049e6803b, topicName=阻断剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Fri Apr 28 10:39:00 CST 2017, time=2017-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710032, encodeId=51ce1e10032d0, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Tue Feb 14 05:39:00 CST 2017, time=2017-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148165, encodeId=74bc148165f6, content=拜读了,受益匪浅,点个赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Oct 14 14:05:44 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589285, encodeId=226d1589285ca, content=<a href='/topic/show?id=fb0389e4373' target=_blank style='color:#2F92EE;'>#血管紧张素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89743, encryptionId=fb0389e4373, topicName=血管紧张素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ce517702394, createdName=xiongliangxl, createdTime=Thu Jun 02 02:39:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]

相关资讯

Hypertension:亚麻籽抗高血压效应显著

加拿大一项研究表明,食用亚麻籽有最显著的抗高血压效应。相关文章10月14日在线发表于《高血压》(HYPERTENSION)杂志。  亚麻籽含有ω-3脂肪酸、木酚素类和纤维,心血管疾病患者食用后可能从中获益。动物实验显示,饮食中补充亚麻籽可使外周动脉疾病患者获益。高血压通常与外周动脉疾病相关。该前瞻性、双盲、安慰剂对照随机研究旨在评估每日食用亚麻籽对周围动脉疾病患者的收缩压(SBP)和舒张压(DBP